CD8A and cancer: Nonetheless, they yield only suboptimal CD8+ Tcell responses against a fraction of the antigenic targets with minimalevidence of therapeutic efficacy.12 Thismay, in part, be related to suboptimal vaccine formulation as we,and others, have demonstrated that copackaging of antigen and adjuvantinto a common carrier enhances cellular immune responses to vaccines.27−35 Collectively, these challenges in antigen and adjuvant deliverymotivate the development and optimization of cancer vaccines to augmentCD8+ T cell responses to peptide neoantigens.